PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast care

Andreas D. Hartkopf¹ 

关键词: Breast cancer;    Immunotherapy;    PD-1;    PD-L1;    Clinical trials;   

DOI  :  10.1159/000453569

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.

【 授权许可】

CC BY